W
WAVEMAN · COMPANY
GALT · Galectin Therapeutics Inc
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

GALT

GALECTIN THERAPEUTICS INC
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001133416
FORM 144 · 4☆ WATCH
INSIDER NET · 180D
-$521.7K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
53
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
CONVERSIONS · 180D
10
codes C/M, not in net · $106.0M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$521.7K over 180 days
-$520.0K over 90 days
below 56% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
53 funds added or opened last quarter
below 54% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
8.6% of shares outstanding short · 23.6 days to cover · settled 2026-07-31
more than 71% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
4 insiders have filed intent to sell ($517.8K) and have not sold yet.
53 funds added or opened positions in the latest 13F quarter, of 100 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -1.6%
-1.6%12M
-53%-20%+14%+47%2025-092025-102025-122026-032026-052026-072026-09 2025-12-03 · 10X Capital Management, LLC sold $756.8K2025-12-03 · 10X Capital Management, LLC sold $687.6K2026-06-29 · Jamil Khurram sold $239.2K2025-11-13 · Jamil Khurram sold $227.0K2025-12-08 · Shlevin Harold H. sold $210.7K2025-11-11 · 10X Capital Management, LLC sold $210.0K2025-12-08 · Shlevin Harold H. sold $208.2K2025-12-16 · CZIRR JAMES C sold $204.3K2025-11-18 · CALLICUTT JACK W sold $174.8K2025-12-02 · 10X Capital Management, LLC sold $164.1K2025-12-02 · 10X Capital Management, LLC sold $164.1K2025-12-08 · Shlevin Harold H. sold $148.8K2025-10-22 · 10X Capital Management, LLC sold $148.2K2025-12-17 · Shlevin Harold H. sold $139.3K2026-01-06 · LEWIS JOEL sold $135.0K2025-12-12 · Shlevin Harold H. sold $124.1K2025-12-08 · Shlevin Harold H. sold $120.0K2025-11-13 · Jamil Khurram sold $119.6K2025-12-08 · Shlevin Harold H. sold $119.2K2025-12-08 · Shlevin Harold H. sold $119.2K2025-11-17 · CALLICUTT JACK W sold $118.8K2025-11-18 · CALLICUTT JACK W sold $113.3K2026-06-29 · Shlevin Harold H. sold $112.2K2026-01-05 · LEWIS JOEL sold $108.4K2025-12-09 · Shlevin Harold H. sold $105.3K2026-01-05 · CALLICUTT JACK W sold $100.4K2026-01-05 · Jamil Khurram sold $99.4K2025-10-22 · 10X Capital Management, LLC sold $98.6K2025-11-17 · LEWIS JOEL sold $94.7K2025-09-12 · LEWIS JOEL sold $89.0K2025-11-13 · Jamil Khurram sold $88.9K2025-11-04 · LEWIS JOEL sold $87.5K2026-07-14 · Jamil Khurram sold $83.3K2026-01-06 · Jamil Khurram sold $78.3K2026-01-02 · LEWIS JOEL sold $78.0K2026-01-06 · CALLICUTT JACK W sold $74.7K2025-11-04 · CALLICUTT JACK W sold $65.2K2025-12-17 · Jamil Khurram sold $59.8K2026-01-02 · CALLICUTT JACK W sold $58.4K2025-11-17 · CALLICUTT JACK W sold $57.8K2025-09-12 · CALLICUTT JACK W sold $56.1K2025-12-17 · LEWIS JOEL sold $55.3K2026-06-29 · Harold Shlevin filed to sell $112.2K2026-06-26 · HAROLD SHLEVIN filed to sell $38.7K2026-06-26 · Jamil Khurram filed to sell $341.4K2026-06-23 · Jamil Khurram filed to sell $25.5K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $521.7K sold by insiders over 180 days, 53 funds added last quarter, $517.8K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, GALECTIN THERAPEUTICS INC insiders sold a net $521.7K of stock across 132 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Jamil Khurram
Chief Medical Officer
SELL
2026-07-14
16,250.0
$83.3K
Shlevin Harold H.
Director
SELL
2026-06-29
22,268.0
$112.2K
Jamil Khurram
Chief Medical Officer
SELL
2026-06-29
47,467.0
$239.2K
Shlevin Harold H.
Director
SELL
2026-06-26
7,732.0
$38.7K
Jamil Khurram
Chief Medical Officer
SELL
2026-06-26
2,037.0
$10.2K
132 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 127 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
2,988,353.0 sh
$13.9M
VANGUARD CAPITAL MANAGEMENT LLC
2,168,065.0 sh
$10.1M
GEODE CAPITAL MANAGEMENT, LLC
1,308,394.0 sh
$6.1M
OSAIC HOLDINGS, INC.
1,203,725.0 sh
$5.6M
MARSHALL WACE, LLP
831,010.0 sh
$3.9M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Harold Shlevin
FILED 2026-06-29
$112.2K
HAROLD SHLEVIN
FILED 2026-06-26
$38.7K
Jamil Khurram
FILED 2026-06-26
$341.4K
Jamil Khurram
FILED 2026-06-23
$25.5K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Horizon Kinetics Medical ETF
$137.3K POSITION · AS OF 2026-03-31
0.8%
Invesco NASDAQ Future Gen 200 ETF
$34.5K POSITION · AS OF 2026-02-28
0.2%
iShares Micro-Cap ETF
$319.3K POSITION · AS OF 2026-03-31
0.0%
1290 VT Micro Cap Portfolio
$23.9K POSITION · AS OF 2026-03-31
0.0%
Small Cap Core Fund
$15.0K POSITION · AS OF 2026-03-31
0.0%
Fidelity Flex Small Cap Index Fund
$17.6K POSITION · AS OF 2026-04-30
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 2 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
0 ACTIVE
1
Multi-phase
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
OPERATING INCOME$-20.1M$-42.4M$-38.1M$-38.4M
NET INCOME$-30.8M$-47.0M$-41.1M$-38.8M
EPS (DILUTED)-0.48-0.76-0.74-0.65
OPERATING CASH FLOW$-23.9M$-41.8M$-33.0M$-31.1M
CASH$17.7M$15.1M$25.7M$18.6M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →